Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEA RNA-pulsed Dendritic Cells in Resected Liver Metastases from Colon Cancer
NCT00003433Phase 2
Key facts
- Status
- Completed
- Start
- Jun 1998
- Countries
- 1
- Sponsor
- Duke Cancer Institute
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, RNA Therapeutics
- Conditions
- colorectal cancer (CRC)
01
Overview
Phase 2, open-label, single-arm trial of carcinoembryonic antigen RNA-pulsed dendritic cells in colorectal cancer (CRC), sponsored by Duke Cancer Institute. Primary endpoint: Cellular immune response to CEA-pulsed dendritic cells at Week 8. Started Jun 1998; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
CEA RNA-pulsed dendritic cells
Autologous dendritic cells pulsed with CEA RNA
03
Who it enrols
Patients with histologically confirmed adenocarcinoma of the colon metastatic to the liver that expresses CEA, who have undergone complete resection with no gross residual disease.
04
Endpoints
Primary
Cellular immune response to CEA-pulsed dendritic cells
Secondary
Overall Survival
Recurrence-Free Survival
Beyond the preview
Go deeper on NCT00003433.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003433.